天津市龙济手术治疗早泄天津市武清区龙济泌尿医院到底怎么样,天津龙济男科破坏,天津市龙济治疗阴虱,包皮切除天津市武清区龙济医院怎么样,天津龙济医院包皮手术要多少钱,武清龙济精液常规,武清区龙济治阳痿

WASHINGTON, April 3 (Xinhua) -- Scientists have confirmed that metabolic syndrome, a constellation of conditions that increases the risk of heart disease and diabetes, may also increase the risk of the two most common types of liver cancer, according to data presented at the American Association for Cancer Research's 102nd Annual Meeting 2011, held in Orlando, Florida on April 2-6.Katherine McGlynn, a senior investigator at the National Cancer Institute, said approximately one-third of the U.S. population has metabolic syndrome, which is defined as the co-occurrence of at least three of the following five conditions: raised blood pressure, elevated waist circumference, low HDL or "good" cholesterol, raised triglyceride levels and raised fasting plasma glucose levels.According to McGlynn, persons with these conditions may be at increased risk of developing hepatocellular carcinoma and intrahepatic cholangiocarcinoma.For the current study, researchers identified 3,649 cases of hepatocellular carcinoma and 743 cases of intrahepatic cholangiocarcinoma. They compared the medical history of these patients with the medical histories of 195,953 cancer-free adults.Statistical analyses showed that the persons with liver cancer were significantly more likely than cancer-free persons to have a prior history of metabolic syndrome: 37.1 percent of patients with hepatocellular carcinoma had pre-existing metabolic syndrome, as did 29.7 percent of patients with intrahepatic carcinoma; only 17.1 percent of the cancer-free adults had metabolic syndrome.Liver cancer incidence has been rising since the 1980s in the United States. The factors related to the increase are not well understood. "A lot of attention has focused on viral risk factors, but a significant part of the increase may be due to metabolic syndrome, as well as to diabetes and obesity," said McGlynn."The prognosis for liver cancer is only marginally better than the prognosis for pancreatic cancer, with a five-year survival of approximately 10 percent," she said. "Prognosis is more favorable, however, when liver cancers are diagnosed at early stages when they are small and localized to the liver."

WASHINGTON, April 25 (Xinhua) -- The U.S. National Aeronautics and Space Administration (NASA) and the U.S. Agency for International Development (USAID) have agreed to expand their joint efforts to overcome international development challenges such as food security, climate change, and energy and environmental management.NASA Administrator Charles Bolden and USAID Administrator Rajiv Shah signed a five-year memorandum of understanding on Monday, at NASA Headquarters. The agreement formalizes ongoing agency collaborations that use Earth science data to address developmental challenges, and to assist in disaster mitigation and humanitarian responses. The agreement also encourages NASA and USAID to apply geospatial technologies to solve development challenges affecting the United States and developing countries."Technologies for NASA missions have long improved life here on Earth. Together with USAID, we'll meet even more sustainable development challenges here on the ground, solving problems for the world community," Bolden said in a statement. "As we explore space, we'll also be exploring solutions to important health, nutritional and safety challenges in developing countries."The agencies will continue collaborations to stimulate innovative science and technology solutions to international development challenges by using Earth science data, research results, computer models, visualization applications and remote- sensing techniques.USAID is the lead federal development agency implementing U.S. development efforts through field-based programs and projects around the world. NASA has broad experience with Earth science research, development of Earth science information products, and technology applications."Through our partnership with NASA, we can apply the latest, cutting-edge technology to deliver meaningful results for people in developing countries in areas like health, food security and water," Shah said. "It's a prime example of our efforts to use the power of science and technology to tackle today's pressing development challenges."Since 2003, NASA and USAID have worked together building and expanding the SERVIR program, which allows people in developing regions to use Earth observations for addressing challenges in agriculture, biodiversity conservation, climate change, disaster response, weather forecasting, and energy and health issues.The agencies also collaborate on the LAUNCH program, which supports science and technology innovators in the nonprofit and private sectors. The program's goal is improving innovations to achieve greater impact on sustainability issues.

BEIJING, April 14 (Xinhuanet) -- The discovery of a sharp-toothed dinosaur fossil in New Mexico, the United States, may bridge a gap in the evolution of the species, researchers said in Wednesday's journal Proceedings of the Royal Society B.Researchers from the Smithsonian Institution unearthed the dinosaur skull and neck vertebrae in Abiquiu, New Mexico, where it had remained buried for around 230 million years. The short snout and slanting front teeth of the find — Daemonosaurus chauliodus — had never before been seen in a Triassic era dinosaur, said Hans-Dieter Sues of the Smithsonian's National Museum of Natural History.Sues, curator of vertebrate paleontology at the museum, said the discovery helps fill the evolutionary gap between the dinosaurs that lived in what is now Argentina and Brazil about 230 million years ago and the later theropods like the famous Tyrannosaurus rex."Various features of the skull and neck in Daemonosaurus indicate that it was intermediate between the earliest known predatory dinosaurs from South America and more advanced theropod dinosaurs," said Sues."One such feature is the presence of cavities on some of the neck vertebrae related to the structure of the respiratory system," he added.The discovery suggests that there is still much to be learned about the early evolution of dinosaurs."The continued exploration of even well-studied regions like the American Southwest will still yield remarkable new fossil finds," Sues said.

WASHINGTON, April 5 (Xinhua) -- NASA and co-researchers from the United States, the Republic of Korea and Japan have found a new mineral named "Wassonite" in one of the most historically significant meteorites recovered in Antarctica in December 1969, the U.S. space agency said on Tuesday in a statement.The new mineral was discovered within the meteorite officially designated Yamato 691 enstatite chondrite. The meteorite likely may have originated from an asteroid orbiting between Mars and Jupiter. Wassonite is among the tiniest, yet most important, minerals identified in the 4.5-billion-year-old sample.The research team, headed by NASA space scientist Keiko Nakamura-Messenger, added the mineral to the list of 4,500 officially approved by the International Mineralogical Association."Wassonite is a mineral formed from only two elements, sulfur and titanium, yet it possesses a unique crystal structure that has not been previously observed in nature," said Nakamura-Messenger.In 1969, members of the Japanese Antarctic Research Expedition discovered nine meteorites on the blue ice field of the Yamato Mountains in Antarctica. This was the first significant recovery of Antarctic meteorites and represented samples of several different types.As a result, the United States and Japan conducted systematic follow-up searches for meteorites in Antarctica that recovered more than 40,000 specimens, including extremely rare Martian and lunar meteorites.Researchers found Wassonite surrounded by additional unknown minerals that are being investigated. The mineral is less than one-hundredth the width of a human hair or 50x450 nanometers. It would have been impossible to discover without NASA's transmission electron microscope, which is capable of isolating the Wassonite grains and determining their chemical composition and atomic structure."More secrets of the universe can be revealed from these specimens using 21st century nano-technology," said Nakamura- Messenger.The new mineral's name was approved by the International Mineralogical Association. It honors John T. Wasson, professor at the University of California, Los Angeles. Wasson is known for his achievements across a broad swath of meteorite and impact research, including the use of neutron activation data to classify meteorites and to formulate models for the chemical makeup of bulk chondrites.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.